ResMed Acquires Noctrix Health in $340M Restless Legs Deal

ResMed — the company behind many of the CPAP machines and masks Australians sleep with every night — has completed its acquisition of Noctrix Health, a US medtech firm whose flagship device treats restless legs syndrome (RLS) without drugs. In a deal valued at up to US$340 million, ResMed is signalling that its ambitions now stretch well beyond the airway, into a sleep disorder that CPAP was never built to treat.

What happened

ResMed announced it had completed the takeover of Noctrix Health in early June 2026, folding the company into its clinical sleep health portfolio. Industry reporting from MedTech Dive and MassDevice put the total value of the deal at up to US$340 million, structured with milestone-based payments tied to commercial and regulatory targets.

Noctrix's product is the Nidra device, which delivers what's known as tonic motor activation (TOMAC) therapy — a non-invasive, non-pharmacologic treatment that received FDA De Novo authorisation for moderate-to-severe restless legs syndrome. It's designed for adults who haven't responded well enough to medication, aiming to ease RLS symptoms and improve sleep quality.

ResMed CEO Mick Farrell framed the move as part of the company's longer-term plan: "Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio." Noctrix CEO Shri Raghunathan said joining ResMed would help "expand access to TOMAC therapy and reach more patients."

Why it matters

Restless legs syndrome is no niche complaint — it's the third most prevalent sleep disorder, affecting roughly 8% of adults. It's also notoriously frustrating to treat: many sufferers don't get adequate relief from medication, and the condition steadily erodes sleep quality night after night.

For a company long defined by CPAP machines, masks and ventilators, buying a drug-free RLS therapy is a notable pivot. It tells you where one of the world's biggest sleep-tech players sees the future heading: away from a single device for a single condition, and towards a broader toolkit covering the many things that wreck a good night's sleep.

What this means for CPAP Club customers

If you buy ResMed gear from us, this is good context to have:

Your machines and masks aren't going anywhere. ResMed's core CPAP business remains the engine of the company — this acquisition adds to the portfolio, it doesn't replace it. Expect the same AirSense and AirFit lines you already rely on.
Sleep apnea and restless legs often overlap. It's not unusual to have both. If you're treating your apnea faithfully but still waking tired with that crawling, can't-keep-still feeling in your legs, RLS could be a separate piece of the puzzle worth raising with your doctor.
The "drug-free" angle is the story. Many RLS patients want options beyond medication. A device-based therapy reflects the same philosophy as CPAP itself — treat the problem mechanically, every night, without a pill.
Watch this space. As big players consolidate sleep care, more of the conditions that interrupt your sleep are coming under one roof. That can mean better-integrated care down the track.

"Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio." — Mick Farrell, ResMed CEO

The bottom line

ResMed's purchase of Noctrix Health is a clear bet that good sleep is about more than clear airways. For CPAP users, the immediate takeaway is reassurance — the brand behind your therapy is investing in sleep health, not stepping back from it. And if restless legs are stealing your rest on top of apnea, it's a timely nudge to mention it at your next appointment. Quality sleep is rarely a one-device problem, and the industry is finally treating it that way.